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Introduction: The Swiss Federal Office of Public Health has recommended vaccination 
against human papillomavirus (HPV) to prevent cervical cancer since 2007. To monitor the 
future public health impact of vaccination, baseline population-based data are required. 
The objectives of this study were to determine the prevalence of HPV and examine associa-
ted risk factors in women with cervical intraepithelial neoplasia stage 3 or more severe lesi-
ons (CIN3+) in Switzerland.
Materials and methods: We conducted a cross-sectional study with women diagnosed 
with CIN3+ in Switzerland. Ten pathology institutes from six cantons and three language re-
gions participated. We conducted HPV typing on formaldehyde fixed-paraffin embedded 
specimens from 2014 and 2015. Women enrolled in 2015 were asked to complete a questi-
onnaire. We described frequencies of HPV types. We also compared demographic characte-
ristics and socioeconomic status (according to the Swiss neighbourhood index of socioeco-
nomic position, Swiss-SEP) in the CIN3+plus group with the Swiss National Cohort (SNC) in 
2014 and compared risk factors for HPV infection with the Swiss Health Survey (SHS) in 2012. 
Results: We included 768 biopsies from 767 women aged 17-81 years with CIN3+ in 2014 
and 2015. Of these, 745 (97.0%) were positive for any HPV type, 5 (0.7%) were negative and 
18 (2.3%) were not evaluable. Overall, 475/768 (61.8%) biopsies contained HPV 16 and/or 18 
and 687 (89.5%) contained an oncogenic HPV type covered by the nonavalent HPV vaccine 
(16, 18, 31, 33, 45, 52, 58). In 2015, 273 women completed a questionnaire. Compared with 
the SNC, fewer women with CIN3+ were born in Switzerland (49.0 vs. 63.4%; p<0.001) and 
more were single (48.9 vs. 28.1%; p<0.001), but mean Swiss-Sep index was similar (64.6±10.8 
vs. 65.2±10.9; p=0.135). Amongst women with CIN3+, higher proportions reported ≥2 se-
xual partners in the last 12 months (15.4% vs. 4.1%), smoking (38.5% vs. 22.0%) and hormo-
nal contraception use in the last 12 months (35.5% vs. 22.4%) than women in the SHS. 
Conclusion: This is the first study of HPV in women with CIN3+ covering all three language 
regions in Switzerland. Women with CIN3+ have levels of socioeconomic position that are si-
milar to the Swiss general population but higher levels of some risk factors for HPV. Surveil-
lance of HPV types in CIN3+ lesions is feasible and can be used to measure the future impact 
of HPV vaccination on clinical outcomes.
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